{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001612940","name":"ProQR Therapeutics N.V.","summary":"ProQR Therapeutics N.V. is a Dutch biopharmaceutical company focused on the discovery and development of RNA-based therapeutics using its proprietary Axiomer RNA editing platform. Founded in February 2012, the company has historically developed treatments for inherited retinal disorders including sepofarsen (LCA), ultevursen (Usher syndrome), and QR-1123 (adRP). Since August 2022, ProQR exclusively focuses on RNA editing, with lead candidate AX-0810 targeting NTCP for cholestatic diseases entering Phase 1 clinical development in December 2025.","people":[],"products":[{"name":"AX-0810","type":"platform","description":"Lead RNA editing product candidate targeting NTCP (na-taurocholate cotransporting polypeptide) for treatment of cholestatic diseases; entered Phase 1 in December 2025."},{"name":"Axiomer","type":"platform","description":"Proprietary RNA editing platform technology used to develop product candidates across multiple therapeutic areas."},{"name":"sepofarsen","type":"platform","description":"Former clinical-stage candidate for Leber Congenital Amaurosis (LCA); clinical development ended and sold to Laboratoires Tha S.A.S. in December 2023."},{"name":"ultevursen","type":"platform","description":"Former clinical-stage candidate for Usher syndrome; clinical development ended and sold to Laboratoires Tha S.A.S. in December 2023."},{"name":"QR-1123","type":"platform","description":"Product candidate for autosomal dominant retinitis pigmentosa (adRP)."},{"name":"QR-313","type":"platform","description":"Former product candidate for epidermolysis bullosa; spun off from the company."},{"name":"eluforsen","type":"platform","description":"Former product candidate for cystic fibrosis; investment ceased."},{"name":"QR-504a","type":"platform","description":"Former product candidate for Fuchs endothelial corneal dystrophy; investment ceased."}],"partnerships":[{"partner_name":"Eli Lilly and Company","partnership_type":"development","description":"Collaboration agreement with potential milestone and royalty payments from commercial product sales covered by the collaboration.","start_date":null},{"partner_name":"Laboratoires Tha S.A.S.","partnership_type":"licensing","description":"Purchased sepofarsen and ultevursen from ProQR in December 2023.","start_date":null}],"affiliations":[],"origin":{"leaf":"cccaedd3d577b46bc785d07430d916c1529c9d575e259816f26d6749987e6403","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"dbcbcabbe781320cc07b7f8f55ba293aed47756baf7f7bbc2b75aab77ecc431b","parent":"0bce6c3db7b2288e9287a25846dedf8eecf1954e3be8dbaa5d3fb4ee5cb3fb47","source":"0001104659-26-026713","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":62,"hourly_limit":500,"remaining":438,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}